Clinical Trial

Use of Empagliflozin to Treat Prediabetes

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 23, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The overall purpose of this study is to identify how empagliflozin (a drug commonly used to treat type 2 diabetes) impacts skeletal muscle metabolic health among adults with prediabetes. Our aims are to: 1) Test the ability of empagliflozin to improve regulation of glucose metabolism (i.e., blood sugar) among overweight and obese individuals at risk for diabetes, and 2) Identify mechanisms to explain how empagliflozin may improve skeletal muscle glucose metabolism. We hypothesize empagliflozin will improve regulation of glucose metabolism due to changes in whole-body and skeletal muscle metabolism (e.g., increased rates of whole-body fat oxidation, evidence of impaired skeletal muscle mitochondrial respiratory function and increased energetic stress, lower accumulation of skeletal muscle lipids and improved skeletal muscle insulin signaling compared with placebo treatment).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-06-16; most recent amendment 2026-01-22.
Status change: Completed → Active, Not Recruiting 2026-01-22
Status change: Recruiting → Completed 2025-06-09
Status change: Not Yet Recruiting → Recruiting 2022-07-19
Trial Details
NCT Number NCT05426525
Lead Sponsor Oregon State University
Collaborators: Samaritan Health Services
Conditions PreDiabetes, Prediabetic State, Overweight and Obesity
Enrollment 60 participants
Start Date 2022-10-13
Primary Completion 2026-05 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-23